Global Ophthalmics Partnering 2014 to 2021 provides the full collection of Ophthalmics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
Trends in Ophthalmics partnering deals Financial deal terms for headline, upfront and royalty by stage of development Ophthalmics partnering agreement structure Ophthalmics partnering contract documents Top Ophthalmics deals by value Most active Ophthalmics dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Ophthalmics deals.
The report presents financial deal terms values for Ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Ophthalmics dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Ophthalmics dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Ophthalmics deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Ophthalmics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Ophthalmics deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Ophthalmics partnering deals by specific Ophthalmics target announced since 2014. The chapter is organized by specific Ophthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Ophthalmics partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Ophthalmics partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Ophthalmics technologies and products.
Report scope Global Ophthalmics Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Ophthalmics trends and structure of deals entered into by leading companies worldwide.
Global Ophthalmics Partnering 2014 to 2021 includes: Trends in Ophthalmics dealmaking in the biopharma industry since 2014 Analysis of Ophthalmics deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Ophthalmics deal contract documents Comprehensive access to over 550 Ophthalmics deal records The leading Ophthalmics deals by value since 2014 Most active Ophthalmics dealmakers since 2014
The report includes deals for the following indications: Age-related macular degeneration, Blindness, Cataracts, Conjunctivitis, Diabetic macular edema, Dry eye, Glaucoma, Ocular hypertension, Retinal detachment Retinopathy, Diabetic retinopathy, Uveitis, plus other ophthalmic indications.
In Global Ophthalmics Partnering 2014 to 2021, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Ophthalmics Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 550 ophthalmics deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are the sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
As the global chemicals industry is at the onset of the recovery phase, companies are focusing on identifying and monetizing new opportunities in the industry. The majority of the chemical industries are likely to record volume growth of 4% to 8% in the short term, depending on the chemical sub-segment and product portfolio. A large volume...
120 pages •
By Infiniti Research Limited
• Apr 2021
Global 3D Printing Medical Devices Market 2021-2025 The analyst has been monitoring the 3D printing medical devices market and it is poised to grow by $ 2.39 billion during 2021-2025, progressing at a CAGR of almost 18% during the forecast period. Our report on the 3D printing medical devices market provides a holistic...
186 pages •
By Global Industry Analysts
• Apr 2021
- Global Urodynamics Equipment and Disposables Market to Reach $180.6 Million by 2027
- Amid the COVID-19 crisis, the global market for Urodynamics Equipment and Disposables estimated at US$128.6 Million in the year 2020, is projected to reach a revised size of US$180.6 Million by 2027, growing at a CAGR...
183 pages •
By Global Industry Analysts
• Apr 2021
- Global Microelectronic Medical Implants Market to Reach $61.5 Billion by 2027
- Amid the COVID-19 crisis, the global market for Microelectronic Medical Implants estimated at US$35 Billion in the year 2020, is projected to reach a revised size of US$61.5 Billion by 2027, growing at a CAGR of 8.4% over the...
2021 Surge Protection Device Market - Size, Share, COVID Impact Analysis and Forecast to 2027 The global Surge Protection Device Market is valued at USD 2.5 billion in 2020 and is expected to reach USD 3.3 billion by 2026 registering a compounded annual growth rate of 4.82%. Major Trends, Drivers and...
The Global Electronic Clinical Outcome Assessment Solution Market (eCOA) size is expected to reach $2.4 billion by 2026, rising at a market growth of 19% CAGR during the forecast period. Electronic clinical outcome assessment (eCOA) refers to a system that is capable of measuring mental state, patient symptom, and the prognosis of a disease....
The global intraoperative imaging market size is projected to reach USD 2.5 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 5.2%. Factors such as the technological advancements in the market are propelling the growth of the intraoperative imaging market. Additionally, rising cases of surgeries, investments from both private and...
The disposable medical device sensors market is projected to reach USD 9.4 billion by 2026 from USD 6.5 billion in 2021, at a CAGR of 7.7% during the forecast period. Market growth is largely driven by rising concerns over hospital-acquired infections and contamination, the increasing incidence of target conditions, the growing demand for...
The implementation of track and trace solutions and technologies is an important strategy adopted by many manufacturing companies and regulatory bodies in recent years. The global track and trace solutions market is projected to reach USD 7.3 billion by 2026 from USD 4.1 billion in 2021, at a CAGR of 12.1% during the forecast period. Growth...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.